

APPENDIX 1. Antineoplastic agents used to exclude patients undergoing treatment for active malignancy (listed alphabetically).

Abarelix	Dactinomycine	Idarubicin hydrochloride	Pazopanib hydrochloride
Aldesleukin	Dasatinib	Ifosfamide	Pegaspargase
Alemtuzumab	Daunorubine citrate/ hydrochloride	Imatinib mesylate	Pemetrexed disodium
Altretamine	Decatabine	Interferon alpha	Pralatrexate
Anastrozole	Degarelix acetate	Irinotecan hydrochloride	Procarbazine hydrochloride
Arsenic trioxide	Denileukin diftitox	Ixabepilone	Sorafenib tosylate
Asparaginase	Docetaxel	Lapatinib ditosylate	Streptozocin
Azacitidine	Doxorubicin hydrochloride	Lenalidomide	Sunitinib malate
Bendamustine hydrochloride	Epirubicin hydrochloride	Letrozole	Tamoxifen citrate
Bevacizumab	Erlotinib	Leuprolide acetate	Temozolomide
Bexarotene	Estramustine phosphate sodium	Lomustine	Temsirolimus
Bicalutamide	Etoposide	Mechlorethamine hydrochloride	Teniposide
Bleomycine sulfate	Everolimus	Megestrol acetate	Thioguanine
Bortezomib	Exemestane	Melphalan	Thiotepa
Busulfan	Fludarabine phosphate	Mercaptopurine	Topotecan hydrochloride
Capecitabine	Fluorouracil	Methotrexate	Toremifene citrate
Carboplatin	Flutamide	Mitomycin	Tositumomab
Carmustine	Fulvestrant	Mitotane	Trastuzumab
Cetuximab	Gefitinib	Mitoxantrone hydrochloride	Tretinoin
Chlorambucil	Gemcitabine hydrochloride	Nelarabine	Triptoreline pamoate
Cisplatin	Gemtuzumab ozogamicine	Nilotinib	Valrubicin
Cladribine	Gosereline acetate	Nilutamide	Vinblastine sulfate
Clofarabine	Histrelin	Ofatumumab	Vinorelbine tartrate
Cyclophosphamide	Hydroxyurea	Oxaliplatin	Vorinostat
Cytarabine	Ibritumomab tiuxetan	Paclitaxel	Rituximab
Dacarbazine		Panitumumab	Romidepsin

APPENDIX 2. Drugs associated with neutropenia or agranulocytosis (listed alphabetically).

β-Lactams	Clozapine	Phenytoin
Carbamazepine	Corticosteroids	Propylthiouracil
Carbimazole	Indomethacin	Sulfasalazine
Clomipramine	Methimazole	Trimethoprim-sulfamethoxazole

APPENDIX 3. Immunosuppressive agents used for exclusions (listed alphabetically).

Alefacept	Cyclophosphamide	Mercaptopurine	Pimecrolimus
Antithymocyte globulin	Cyclosporine	Methotrexate	Sirolimus
Azathioprine	Infliximab	Mofetil mycophenolate	Tacrolimus
Basiliximab	Leflunomide		

Appendix to: Roy MP, Calon F, Simonyan D, Bergeron L. Risk of neutropenia in adults treated with piperacillin–tazobactam or cefazolin: a retrospective cohort study. *Can J Hosp Pharm.* 2022;75(3):186-92.